By Nicholas G. Miller
American depositary receipts of RedHill Biopharma climbed after the company said it received positive Food and Drug Administration feedback on its treatment for Crohn's disease.
The ADRs were up 24%, to $2.30, midday Monday. They have slipped about 63% so far this year.
The Israeli company said the positive feedback would allow it to undertake a phase two study of the drug, called RHB-204, which has already received positive phase three safety and efficacy results. RedHill has a patent for the drug until 2041.
Write to Nicholas G. Miller at nicholas.miller@wsj.com
(END) Dow Jones Newswires
July 21, 2025 12:20 ET (16:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。